Onychomycosis is the most commonly prevalent nail infection in adults. It is a fungal infection that leads to discoloration and thickening of the nail plate. As per the DelveInsight, the total Onchomycosis prevalent cases in the G8 (i.e the US, EU-5, Japan, and China) were estimated to be 93,633,252 cases in 2020, which is further expected to increase in the coming next decade.
The Onychomycosis therapy market is expected to increase at a CAGR of 4.1% in the eight major countries during the forecast period 2021-30, with the US occupying the majority of the therapy market share.
Key factors such as the influx of pharma and biotech companies, the launch of emerging novel therapies, and the increase in healthcare expenditure are expected to drive the market growth and revenue.
Some of the prominent pharmaceutical and biotech companies such as Pfizer, Bausch Health Companies Inc., Sato Pharmaceutical Inc, Eisai US, Moberg Pharma AB, Blueberry Therapeutics Ltd, Mycovia Pharmaceuticals, Meiji Seika Kaisha, NovaBiotics, Hallux, and others are working in the Onychomycosis therapy market to meet the unmet needs.
Read More: Onychomycosis Therapeutics Pipeline Analysis